Top Markets
#1 Status Status +19.98%
#2 Civic Civic +4.94%
#3 Hex Trust USD Hex Trust USD +4.50%
#4 Bitway Bitway +3.41%
#5 龙虾 (Lobster) 龙虾 (Lobster) +3.15%
#6 MANTRA MANTRA +2.96%
#7 Raydium Raydium +2.65%
#8 Infinity Ground Infinity Ground +2.33%
#9 Holo Holo +2.24%
#10 Freedom of Money Freedom of Money +2.14%
Coin of the day
Status Status
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rang în acțiuni #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Preț acțiune
$451.59
Capitalizare de piață
$114.70B
Schimbare (1 zi)
-2.36%
Schimbare (1 an)
-11.89%
Țară
US
Tranzacționează Vertex Pharmaceuticals Incorporated (VRTX)

Categorie

Healthcare
Număr de acțiuni în circulație pentru Vertex Pharmaceuticals Incorporated (VRTX)
Număr de acțiuni în circulație la data de December 2025: 253.90M
Conform celor mai recente rapoarte financiare și prețului acțiunilor Vertex Pharmaceuticals Incorporated, numărul curent de acțiuni în circulație este 253.90M. La sfârșitul anului December 2024, compania avea 257.50M acțiuni în circulație. Numărul de acțiuni în circulație este de obicei influențat de splituri de acțiuni și programe de răscumpărare.
Istoricul acțiunilor în circulație pentru Vertex Pharmaceuticals Incorporated (VRTX) din 2000 până în 2026
Acțiuni în circulație la sfârșitul fiecărui an
An Acțiuni în circulație Schimbă
2026 (TTM) 253.90M -0.70%
2025 255.70M -0.70%
2024 257.50M -0.08%
2023 257.70M 0.62%
2022 256.10M -0.62%
2021 257.70M -0.82%
2020 259.84M 1.21%
2019 256.73M 0.96%
2018 254.29M 2.18%
2017 248.86M 2.16%
2016 243.59M 1.14%
2015 240.84M 2.52%
2014 234.92M 4.49%
2013 224.83M 6.08%
2012 211.95M 3.44%
2011 204.89M 2.24%
2010 200.40M 15.67%
2009 173.26M 23.27%
2008 140.56M 8.97%
2007 128.99M 13.92%
2006 113.22M 26.87%
2005 89.24M 13.58%
2004 78.57M 2.03%
2003 77.00M 1.66%
2002 75.75M 1.73%
2001 74.46M 10.02%
2000 67.68M 0.00%
Acțiuni în circulație pentru companii similare sau concurente
Companie Acțiuni în circulație Diferență Țara
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 1,651.81%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -59.47%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -25.17%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 90.46%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M -75.81%
NL